Ackermann Michael
Related Filers (2)
Ownership (20)
4
Friday, 7/1/2022
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Friday, 6/17/2022
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Monday, 5/9/2022
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
SC 13G/A
Monday, 2/14/2022
Tarsus Pharmaceuticals, Inc.: Major Shareholders
4
Friday, 12/3/2021
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Wednesday, 11/3/2021
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 10/14/2021
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Tuesday, 10/12/2021
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Friday, 9/3/2021
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 8/12/2021
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Tuesday, 8/10/2021
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Friday, 8/6/2021
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 6/17/2021
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
SC 13G
Friday, 2/12/2021
Tarsus Pharmaceuticals, Inc.: Major Shareholders
4
Tuesday, 10/20/2020
Tarsus Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
3
Thursday, 10/15/2020
Tarsus Pharmaceuticals, Inc.: Initial statement of beneficial ownership of securities
4/A
Wednesday, 6/10/2020
Oyster Point Pharma, Inc.: Statement of changes in beneficial ownership of securities
4
Wednesday, 6/10/2020
Oyster Point Pharma, Inc.: Statement of changes in beneficial ownership of securities
4
Monday, 11/4/2019
Oyster Point Pharma, Inc.: Statement of changes in beneficial ownership of securities
3
Wednesday, 10/30/2019
Oyster Point Pharma, Inc.: Initial statement of beneficial ownership of securities